2026 Kidney and Urinary Tract Center Symposium: The Kidney-Cancer Connection – Translating Research into Clinical Impact

Thursday, March 19, 2026, 4:00 PM - Friday, March 20, 2026, 5:00 PM, Nationwide Children's Hospital Conference Center, Columbus, OH


AMA PRA Category 1 Credits™ (6.75 hours), AAPA Credit(s) (6.75 hours), ACPE Contact Hour(s) (6.75 hours), ANCC Contact Hour(s) (6.75 hours), Non-Physician Attendance (6.75 hours)

This symposium will showcase state-of-the-art mechanistic insights and management strategies for kidney and urological complications in pediatric oncology. It will feature cutting-edge approaches and address gaps in early risk detection and timely intervention to improve cancer treatment tolerability, long-term outcomes, and quality of life 

Target Audience: Physicians, providers, and researchers in nephrology, urology, pharmacology, oncology, hematology, and bone marrow transplant (BMT)

1. Identify signs and characteristics of acute and long-term kidney and urological complications in pediatric patients with cancer
2. Assess how cancer and anti-cancer therapies can result on kidney and urological complications
3. Implement strategies that reduce the implications of kidney and urological complications on pediatric oncology patients' care
4. Identify emerging approaches to prevent or mitigate acute kidney injury and chronic kidney disease
5. Analyze how anti-cancer therapies can be maximized by nephroprotective approaches
6. Assess the impact of kidney complications and urological complications on patients and caregivers
7. Strengthen interprofessional communication and collaboration among oncology, nephrology, urology, nursing, and allied health teams to ensure coordinated, patient-centered strategies for early detection, prevention, and management of kidney and urological complications in pediatric cancer care.

Abstracts Categories include: basic science and preclinical research translational research, clinical research, case series, relevant case reports, and quality improvement projects

In support of improving patient care, Nationwide Children's Hospital is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the American Nurses Credentialing Center (ANCC), and the Accreditation Council for Pharmacy Education (ACPE), to provide continuing medical education for the healthcare team.

AAPA Statement

Nationwide Children's Hospital has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 6.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.   

Cancellation Policy

Cancellations received in writing no less than 20 days before the course will be refunded, less a 20% administrative fee. No refunds will be made on cancellations received after that date. Please send cancellation requests to [email protected].

Nationwide Children's Hospital reserves the right to cancel or postpone this program if necessary; in the event of cancellation, course fees will be fully refunded. We are not responsible for other costs incurred such as non-refundable airline tickets or hotel penalties.

Accessibility Statement
 
Nationwide Children's Hospital is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require special accommodations, including dietary concerns, please contact the CME Conference Coordinator.

You are not logged in.

Please click the button below to login or create a new account before continuing.

The Nationwide Children's Hospital® adheres to ACCME Criteria, Standards and Policies regarding industry support of continuing medical education. Disclosure of faculty and their commercial relationships will be made prior to the activity.

Mitigation of Relevant Financial Relationships

Nationwide Children's Hospital adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Exhibit at this Event

Welcome

The scientific committee of the 2026 Kidney and Urinary Tract Symposium, focusing on the field of Onco-nephrology “The Kidney-Cancer Connection: Translating Research into Clinical Impact” invites submissions of original research abstracts for poster presentation at the meeting on March 19 and 20, 2026.

Abstract submissions for poster presentations must be received by January 31st, 2026 , and authors will be notified of acceptance no later than February 15, 2026. All presenters must be registered to attend the conference in person (not virtually). Full submission guidelines are available on the submission site.

The goal of this symposium is to highlight state-of-the art mechanisms and management strategies for kidney complications and urological complications in pediatric oncology. The symposium will address practice gaps in early identification of at-risk patients, understanding kidney and urological complications across diverse clinical scenarios, and implementing timely protective interventions.  These strategies aim to enhance the tolerability of cancer therapies, reduce long-term kidney and urological complications, and ultimately improve patient outcomes and quality of life. The interactive conference program highlights the latest clinical and scientific advances in this growing field. Our program will include a combination of expert presentations, panel discussions, research abstract presentations, and social events to facilitate learning, networking, and collaboration. We expect to attract participants from across the nation with both in-person events and a virtual platform allowing full engagement of remote attendees.

Instructions

The poster session aims to enhance attendees’ understanding of the impact of cancer and modern anti-cancer therapies on acute and long-term kidney and urological complications in pediatric patients. It will also emphasize nephroprotective strategies that can optimize cancer treatment, improve patient tolerability, and support the quality of life of children, adolescent, and young adults with cancer. Abstracts will be selected primarily based on their educational value for conference attendees.

 

Abstract Categories Include:

• Basic Science and Preclinical Research
• Translational Research
• Clinical Research
• Case Series
• Relevant Case Reports
• Quality improvement projects

 

Projects may have been presented previously in poster or printed form. There is no restriction on publication or embargo on abstracts accepted for this meeting.

 

Authors of accepted abstracts will be provided an invitation from conference organizers to present their work. A minimum of one (1) author must be present at the conference in Columbus, Ohio on March 19-20, 2026, to participate in the poster session. If accepted, all travel costs will be the responsibility of the submitting author.

 

A select set of abstracts will also be chosen for oral presentation in Lightning Round format - 1 minute presentation with 1 accompanying slide. Questions can be taken by the presenter during the poster session.

 

Submission Requirements
For each author, include

• First Name Last Name, Degree
• Organizational affiliations

 

For the corresponding author, also include the email address
 

Abstracts must include:

• Title
• Background
• Methods
• Results
• Optional: You may include 1 figure or table, and it must be in PDF or JPEG format
• Conclusions
•  Acknowledgements (if appropriate)

Eligibility:

• Abstracts containing basic, clinical, or translational research related to pediatric, adolescent, and young adult oncology, with a focus on kidney and urinary tract complications. Submissions should aim to advance understanding of pathophysiology, explore emerging strategies for mitigation and prevention, and demonstrate how nephroprotective approaches can enhance cancer treatment effectiveness and improve patient care.
• Abstracts that have been submitted to or presented at other national or international meetings may be submitted, provided that prior presentation and/or submission to other meetings is declared during the submission process.
• Trials in progress may be presented.
• Quality improvement projects may be presented.
• Case series and case reports of particular significance will also be considered.
• Abstracts will not be considered for presentation if they have been published as an article or have been accepted for publication (including manuscripts) in printed or electronic formats upon the submission deadline. 

Formatting:

• Abstract titles may not be longer than 250 characters, including spaces. Identifying information like author or institution names must not be included in the title.
• There is a limit of 2,900 characters, including spaces, for the abstract text. The Title and Information included in tables or images do not count toward this limit. Acknowledgements do count toward this limit.
• Abstracts may include up to 1 image per abstract, only in PDF or JPEG format.
• Any author wishing to include a table with their abstract must submit the table as a PDF or JPEG.
• Authors are responsible for obtaining any necessary image permissions for inclusion in their abstracts. 
• Drug products mentioned in abstracts should be identified by their nonproprietary (i.e., generic) names only. Do not capitalize nonproprietary names.

Presentation rules:

• Posters and Lightning Round presentations must be presented by at least one of the authors in person.
• Submission of an abstract constitutes a commitment by the author(s) to register and present the abstract (if selected for presentation) on the date, time, and location specified in the acceptance notification.
• Abstracts may be presented only by authors listed in the author string at the time of submission.
• All presentations will be in English. Oral abstract presentations must be made by an author who speaks and understands English.
• The corresponding author certifies that all authors named in the abstract have agreed to its submission for presentation; that any animal studies conform with the October 2014 revision of The Guiding Principles in the Care and Use of Vertebrate Animals in Research and Training by the American Physiological Society; and that any human experimentation conducted conforms with the principles of the Declaration of Helsinki of the World Medical Association, and meets all the requirements governing informed consent of the country in which the research was performed.
• By submitting an abstract, the corresponding author affirms that his co-authors have participated sufficiently in the intellectual content, the analysis of data and the writing of the abstract to take public responsibility for it.
• Corresponding authors affirm that they and the other authors submitting an abstract certify that the data included in their abstract submission and/or presented is truthful, original, unduplicated, and without fraud or fabrication.

Submit your Abstract

View Submitted Abstracts